Close Menu
Home » Signature Dx to Use Affymetrix Chips for Cancer Test Development

Signature Dx to Use Affymetrix Chips for Cancer Test Development

Jun 28, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Affymetrix and Signature Diagnostics today announced that they have inked an agreement under which Signature Dx has gained a worldwide license to use Affymetrix's microarray technology to develop and commercialize diagnostic and prognostic colorectal cancer tests.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Unexpected Close

GenomeWeb reports that Veritas Genetics is suspending its US operations.

Sweet Assembly

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Oh, You're Aging Well

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

Science Papers Describe MicroRNA Targeting Efficiency, Approach for Single-Cell High-Throughput Chemical Screens

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.